Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
NCT: NCT05281731 · RECRUITING
Brief Summary
This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.
Frequently Asked Questions
What is Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma?
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma is a clinical trial registered under NCT05281731. Current status: RECRUITING.
What is the status of NCT05281731?
The current status of NCT05281731 (Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma) is: RECRUITING.
When did Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma start?
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma started on 2022-04-18.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.